Biochemical markers and comorbidities for anticipation of pregnancy outcome in recurrent early pregnancy loss: Hypothetical replicated artistic projection

Abstract

Objective: To predict pregnancy outcomes in patients with a history of recurrent pregnancy loss by investigating the relationship between serum HCG, progesterone, and CA125 and the incidence of miscarriage in the first trimester.

Design: Prospective controlled trial was used as the study's design.

Setting: Tertiary University Hospital is the setting; December 2021-January 2022.

Materials and Methods: Serum HCG, progesterone, and CA125 levels in 20 pregnant women with a history of recurrent pregnancy loss were compared to 20 pregnant women with no history of abortion, as well as another group of women (No=20) who failed to complete the first trimester of pregnancy during the research.

Results: Serum B-hCG demonstrated a sensitivity of 100 percent, a specificity of 50 percent, a PPV of 50 percent, and an NPV of 100 percent. Serum progesterone had a sensitivity of 25%, a specificity of 78%, a PPV of 36%, and an NPV of 67%, while serum CA125 had a sensitivity of 10%, a specificity of 65%, a PPV of 13%, and an NPV of 59%.

Conclusion: The value of CA125 in recurrent abortions is yet unknown and should not be used on a regular basis. Beta-HCG, on the other hand, is 100 percent sensitivity with a 50% NPV as a single serum test for predicting pregnancy outcomes.